Keyphrases
Clinical Outcomes
100%
Hepatocellular Carcinoma
100%
Primary Liver Cancer
100%
Yttrium-90 Radioembolization
100%
Cholangiocarcinoma
85%
Biphenotypic Tumors
57%
Confidence Interval
42%
Radioembolization
42%
Carcinoma
42%
Local Progression
42%
Tumor
14%
Yttrium-90
14%
Clinical Response
14%
Overall Survival
14%
Progression Rate
14%
Maximum Tolerated Dose
14%
Clinical Data
14%
Toxic Effects
14%
Ascites
14%
Alpha-fetoprotein
14%
Local Control
14%
Common Terminology Criteria for Adverse Events (CTCAE)
14%
Hyperbilirubinemia
14%
Dose-escalation Trial
14%
Local Tumor Control
14%
Nodal Stage
14%
Unresectable Hepatocellular Carcinoma
14%
Tumor Effect
14%
Multivariate Cox Analysis
14%
United Network for Organ Sharing
14%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
14%
Hepatocellular Cholangiocarcinoma
14%
Local Tumor Progression
14%
Medicine and Dentistry
Liver Cancer
100%
Yttrium 90
100%
Hepatocellular Carcinoma
100%
Radioembolization
100%
Cholangiocarcinoma
87%
Neoplasm
75%
Carcinoma
37%
Liver Tumor
37%
Adverse Event
12%
Overall Survival
12%
Proportional Hazards Model
12%
Toxicity
12%
Tumor Progression
12%
Cancer Staging
12%
Fetoprotein
12%
Ascites
12%
Hyperbilirubinemia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Yttrium 90
100%
Liver Cancer
100%
Liver Cell Carcinoma
100%
Bile Duct Carcinoma
87%
Neoplasm
75%
Carcinoma
37%
Liver Tumor
37%
Tumor Growth
12%
Adverse Event
12%
Maximum Tolerated Dose
12%
Overall Survival
12%
Toxicity
12%
Hyperbilirubinemia
12%
Cancer Staging
12%
Ascites
12%
Fetoprotein
12%